Compare THRM & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRM | MNMD |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 1993 | N/A |
| Metric | THRM | MNMD |
|---|---|---|
| Price | $38.75 | $13.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $39.00 | $30.33 |
| AVG Volume (30 Days) | 169.4K | ★ 2.1M |
| Earning Date | 02-18-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $1,468,728,000.00 | N/A |
| Revenue This Year | $3.56 | N/A |
| Revenue Next Year | $2.52 | N/A |
| P/E Ratio | $39.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.75 | $4.70 |
| 52 Week High | $41.09 | $15.29 |
| Indicator | THRM | MNMD |
|---|---|---|
| Relative Strength Index (RSI) | 58.14 | 60.38 |
| Support Level | $35.86 | $13.06 |
| Resistance Level | $37.57 | $15.29 |
| Average True Range (ATR) | 0.97 | 0.84 |
| MACD | 0.11 | 0.10 |
| Stochastic Oscillator | 71.55 | 60.49 |
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).